Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis

NCT02745080 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

853

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriatic Arthritis

Interventions

BIOLOGICAL: Secukinumab
BIOLOGICAL: Adalimumab

Sponsor

Novartis Pharmaceuticals